Related Experiment Video
Updated: May 12, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing
Zhang Jian-Wei1, Zhou Yu-Jie, Cao Shu-Jun
11Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing, China.
Insights
Pre-procedure high-sensitivity C-reactive protein (hsCRP) levels predict contrast-induced nephropathy (CIN) risk in ST-segment elevation myocardial infarction (STEMI) patients. Higher hsCRP levels correlate with increased CIN incidence after primary percutaneous coronary intervention (p-PCI).
Area of Science:
- Cardiology
- Nephrology
- Biomarkers
Background:
- Contrast-induced nephropathy (CIN) is a complication following periprocedural myocardial infarction.
- High-sensitivity C-reactive protein (hsCRP) is an inflammatory marker associated with cardiovascular events.
Purpose of the Study:
- To evaluate the association between preprocedural hsCRP levels and CIN incidence in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (p-PCI).
Main Methods:
- Retrospective analysis of 1452 STEMI patients undergoing p-PCI.
- Patients were stratified into hsCRP quartiles.
- CIN incidence and inhospital outcomes were compared across quartiles.
Main Results:
- Overall CIN incidence was 14.6% (212 patients).
- CIN incidence increased significantly with higher hsCRP quartiles (Q1: 7.44% to Q4: 21.49%; P < .001).
- Adjusted analysis identified hsCRP >6.50 mg/L as a significant predictor of CIN.
Conclusions:
- Preprocedural hsCRP is a significant independent predictor of CIN in STEMI patients undergoing p-PCI.
- Elevated hsCRP levels are associated with increased risk of CIN and inhospital complications.
Abstract:
We assessed the impact of preprocedural high-sensitivity C-reactive protein (hsCRP) on the incidence of contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (p-PCI). We retrospectively studied 1452 patients with STEMI undergoing p-PCI. Baseline clinical characteristics, CIN incidence, and other inhospital clinical outcomes were compared among hsCRP quartiles; 212 (14.6%) patients developed CIN. The overall inhospital mortality rate was 4.5% (65 patients). Univariate analysis revealed CIN incidence was significantly associated with hsCRP, with 7.44% for quartile Q1 (<3.00 mg/L), 12.6% for Q2 (3.00-5.90 mg/L), 16.9% for Q3 (5.91-11.4 mg/L), and 21.49% for Q4 (>11.4 mg/L; P < .001). Patients with a higher hsCRP experienced a higher rate of inhospital complications. After adjusting for potential confounders, hsCRP >6.50 mg/L was significantly associated with the occurrence of CIN. Preprocedural hsCRP levels are significantly related to the incidence of CIN in patients with STEMI undergoing p-PCI.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies for Cardiovascular System V: CT
Acute Coronary Syndrome III: Diagnostic Studies

